Search
Influenza A virus A/Victoria/2454/2019 IVR-207 (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15705ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: FLUAD Injektionssuspension in einer Fertigspritze, Sandovac Injektionssuspension in einer FertigspritzeNitazoxanide
go.drugbank.com/drugs/DB00507ApprovedInvestigationalVet approvedNitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment … This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated.
Products: N/aLolium perenne pollen
go.drugbank.com/drugs/DB10389ApprovedLolium perenne pollen is the pollen of the Lolium perenne plant. Lolium perenne pollen is mainly used in allergenic testing.
Mixtures: ORALAIR 100 IR + 300 IR Sublingualtabletten, ORALAIR 100 IR + 300 IR SublingualtablettenDimetacrine
go.drugbank.com/drugs/DB08996ApprovedWithdrawnDimetacrine is a tricyclic antidepressant (TCA) with imipramine-like effects used in Europe for the treatment of depression. Dimetacrine is no longer used in Japan. … Dimetacrine is also known as dimethacrine or acripamine. It is marketed under the names Istonil, Istonyl, Linostil, and Miroistonil.
Synonyms: 3-(9,9-dimethylacridin-10-yl)-N,N-dimethyl-propan-1-amineInfluenza B virus B/Victoria/705/2018 BVR-11 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15706ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: FLUAD Injektionssuspension in einer Fertigspritze, Sandovac Injektionssuspension in einer FertigspritzeInfluenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10793ApprovedInvestigationalInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: VaxigripTetra Injektionssuspension in einer Fertigspritze, Influvac Tetra Injektionssuspension in einer FertigspritzeInfluenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15515ApprovedInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Influvac Tetra, suspension for injection in pre-filled syringe, INFLUVAC TETRA, SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE 0.5 MLGolodirsen
go.drugbank.com/drugs/DB15593ApprovedInvestigationalThis is an X-linked condition leading to progressive muscle degeneration that begins in early childhood, rendering many patients wheelchair-bound by age 12. … [A188580,T756] A similar drug used in the treatment of other types of DMD is [eteplirsen], which targets a different genetic mutation.
Categories: Compounds used in a research, industrial, or household settingEntacapone
go.drugbank.com/drugs/DB00494ApprovedInvestigationalEntacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols.
Mixtures: LEV/CAR/EN AL100/25/200, LEV/CAR/EN AL200/50/200Synonyms: (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide, N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamideAgomelatine
go.drugbank.com/drugs/DB06594ApprovedInvestigationalAgomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005. … In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011.